Novel mutant KRAS addiction signature predicts response to the combination of ERBB and MEK inhibitors in lung and pancreatic cancers.
Saved in:
| Title: | Novel mutant KRAS addiction signature predicts response to the combination of ERBB and MEK inhibitors in lung and pancreatic cancers. |
|---|---|
| Authors: | Tyc KM; Department of Pharmacology and Toxicology, and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA., Kazi A; Department of Pharmacology and Toxicology, and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA., Ranjan A; Department of Pharmacology and Toxicology, and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA., Wang R; Department of Pharmacology and Toxicology, and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA., Sebti SM; Department of Pharmacology and Toxicology, and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA. |
| Source: | IScience [iScience] 2023 Jan 31; Vol. 26 (3), pp. 106082. Date of Electronic Publication: 2023 Jan 31 (Print Publication: 2023). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Cell Press Country of Publication: United States NLM ID: 101724038 Publication Model: eCollection Cited Medium: Internet ISSN: 2589-0042 (Electronic) Linking ISSN: 25890042 NLM ISO Abbreviation: iScience Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 2589-0042 |
|---|---|
| DOI: | 10.1016/j.isci.2023.106082 |
